Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...

As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

Former executives of the pharmaceutical giant are backing a push by activist investor Starboard Value to turn aro ...

The drugmaker’s shares have slumped as demand for Covid-19 vaccines and treatments had slowed.

Pfizer is looking to use AI in a Singapore initiative to shorten the drug discovery process. Read more at straitstimes.com.

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...

Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...